Barinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Significant Drop in Short Interest

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the target of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 4,000 shares, a decline of 13.0% from the September 30th total of 4,600 shares. Approximately 0.0% of the company's stock are sold short. Based on an average trading volume of 29,200 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Catalina Capital Group LLC acquired a new position in shares of Barinthus Biotherapeutics in the second quarter valued at approximately $25,000. Ipswich Investment Management Co. Inc. acquired a new position in Barinthus Biotherapeutics in the 2nd quarter valued at $32,000. BlueCrest Capital Management Ltd bought a new position in Barinthus Biotherapeutics during the 1st quarter worth $1,292,000. DC Funds LP acquired a new stake in shares of Barinthus Biotherapeutics during the first quarter worth $1,528,000. Finally, Alphabet Inc. bought a new stake in shares of Barinthus Biotherapeutics in the second quarter valued at about $2,119,000. 25.20% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on BRNS. HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of Barinthus Biotherapeutics in a research report on Thursday, September 26th. Alliance Global Partners decreased their target price on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a "buy" rating for the company in a research note on Tuesday, August 13th.

Barinthus Biotherapeutics Stock Performance

Barinthus Biotherapeutics stock traded up $0.04 during midday trading on Tuesday, reaching $1.45. 10,585 shares of the company's stock were exchanged, compared to its average volume of 24,005. The stock's 50-day simple moving average is $1.26 and its 200 day simple moving average is $1.64. The firm has a market cap of $57.16 million, a price-to-earnings ratio of -0.87 and a beta of -0.53. Barinthus Biotherapeutics has a 52 week low of $1.11 and a 52 week high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.01). Research analysts forecast that Barinthus Biotherapeutics will post -1.71 earnings per share for the current year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.